C3 to Participate in Externally-Led PFDD Meeting with FDA

If you are living with LGMD2A/R1, you will have the opportunity to participate in an externally-led Patient-Focused Drug Development Meeting (EL-PFDD) with the FDA on September 23, 2022. C3 is proud to be one of six LGMD organizations to collaborate on this important venture.

*What will happen at this externally-led PFDD meeting?
This important effort will give individuals diagnosed with limb-girdle muscular dystrophy types 2A, 2C, 2D, 2E, 2F, and 2I an opportunity to share with the FDA about the experiences and challenges of living with LGMD.

*Where will the meeting take place?
The meeting will take place virtually and will be live. Participants will be able to watch the event as it occurs.

*How can I get involved?
You will also be able to participate in polling and participate in surveys prior to the event to share your needs as an individual living with LGMD with the FDA. Many individuals will be selected to speak to the FDA either through prerecorded video or during live segments in the EL-PFDD.

*What do we hope to gain?
The EL-PFDD meeting is designed to engage patients and elicit their unique perspectives. With this information, our goal is to enable the FDA to knowledgeably review and approve LGMD therapies that meet the needs and expectations of our patient community.

Your voice will make a difference! CLICK HERE to receive communications from the LGMD Coalition to learn how you can participate in the externally-led PFDD meeting.

C3 to Participate in Externally-Led PFDD Meeting with FDA

Tagged on: #CureCalpain3 #CureLGMD #CureLGMD2A